Extrapolation and dosing recommendations for raxibacumab in children from birth to age <18 years

• Published in: British journal of clinical pharmacology Vol. 87; no. 12; pp. 4709 - 4717
• Main Authors: Oosterholt, Sean P., Della Pasqua, Oscar
• Format: Journal Article
• Language: English
• Published: England 01.12.2021
• Subjects: Adolescent; Animals; Anthrax - drug therapy; Anthrax - prevention & control; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Bacillus anthracis; Child; Child, Preschool; clinical trial simulations; dose rationale; Humans; Infant; Infant, Newborn; maturation function; Models, Biological; paediatric extrapolation; population pharmacokinetics; raxibacumab; raxibacumab; maturation function; paediatric extrapolation; clinical trial simulations; dose rationale; population pharmacokinetics
• ISSN: 0306-5251; 1365-2125; 1365-2125
• DOI: 10.1111/bcp.14893

Aims The US Food and Drug Administration's Animal Rule allows for the approval of drugs when human efficacy studies are not ethical. While the therapeutic doses of raxibacumab, a monoclonal antibody for the prophylaxis and treatment of inhalational anthrax, have been based on pharmacokinetic data from adult subjects, its disposition in children has not been investigated in clinical trials. Here we evaluate the effect of demographic covariates and maturation processes on the pharmacokinetics of raxibacumab and explore opportunities for the optimisation of paediatric doses. Methods A population pharmacokinetic model was used as basis for the extrapolation of raxibacumab disposition from adults to children. Different extrapolation scenarios, including weight‐banded dosing regimens, were considered to assess the effect of growth and maturation on the pharmacokinetic parameters of interest. Area under the concentration–time curve, maximum plasma concentration and the time of serum raxibacumab concentrations greater than or equimolar to the highest serum protective antigen concentrations observed for at least 28 days in any monkey challenged with Bacillus anthracis that died were derived and compared with the currently approved US doses. Results Based on practical considerations, a weight‐banded dosing regimen consisting of 4 dose levels (75 mg/kg for individuals ≤1.5 kg, 55 mg/kg for individuals <10 kg, 45 mg/kg for individuals <50 kg, 40 mg/kg for all individuals >50 kg) was required to optimise target exposure across the paediatric population. Conclusions Age‐related maturation processes may affect raxibacumab clearance in very young patients. The proposed dosing regimens take into account effects of body weight and maturation processes on the elimination of raxibacumab.